ARS Pharmaceuticals, Inc.
NASDAQARS Pharmaceuticals enters the post-Q1 period in a compressed vice: a quarterly earnings miss sent the stock down 6.5% on Friday to $7.43, while the lending market for its shares is as tight as it has been all year. The week's defining event was the May 15 Q1 print. Revenue of $22.7M edged past the $22.2M estimate, but the EPS miss — $(0.61) against a $(0.52) consensus — landed…
SPRY short interest utilization hits 100%, matching 52-week high, as 26.9% of free float remains shorted.
Snapshot as of 16 May 2026
ARS Pharmaceuticals enters the post-Q1 period in a compressed vice: a quarterly earnings miss sent the stock down 6.5% on Friday to $7.43, while the lending market for its shares is as tight as it has been all…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SPRY — free to start on ORTEX.
Sign up for free →Open SPRY on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live SPRY data →